ROCKVILLE, Md.--(EON: Enhanced Online News)--Immunomic Therapeutics, Inc. (ITI), a privately-held, Maryland-based biotechnology company, announces that C. Eric Winzer, M.B.A., currently serving Immunomic as Chief Financial Officer, will join the Board of Directors.
“The Board has appreciated his prior contribution to our meetings and we are pleased to formally add him to this important advisory team.”
“Mr. Winzer’s keen financial expertise and broad industry experience will be a valuable addition to the Immunomic Board of Directors,” announced Immunomic CEO, Dr. William Hearl. “The Board has appreciated his prior contribution to our meetings and we are pleased to formally add him to this important advisory team.”
C. Eric Winzer, M.B.A., is a 30-year veteran of life science companies, familiar with executing a wide array of financial strategies including raising capital, financial reporting, investor relations, banking, taxation, mergers and acquisitions, financial planning, analysis and accounting operations. As Chief Financial Officer, Winzer has adroitly managed ITI budgets to create a notable return to investors, following the out-licensing of LAMP technology as applied to allergy with Astellas. Prior to joining Immunomic, Mr. Winzer served as Chief Financial Officer of OpGen and Executive Vice President and Chief Financial Officer of Avalan Pharmaceuticals, Inc. He received his B.A. in Economics and Business Administration from McDaniel College and his M.B.A. from Mount Saint Mary’s University.
Board members also include William Hearl, Ph.D., W. Barry McDonald, James W. Wishart, Ronald P. Thiboutot, Ph.D. and Michael D. Lack.
Immunomic Therapeutics, Inc. is a privately-held, clinical stage biotech company on a mission to pioneer vaccines that transform lives. The company, based in Rockville, MD, is developing nucleic acid vaccines based on the patented Lysosomal Associated Membrane Protein (LAMP) Technology. Termed LAMP-Vax™, the exclusive immunotherapy technology works with the body’s natural biochemistry system and has the potential to improve a broad range of vaccines. ITI entered into a licensing agreement with Astellas Pharma Inc. in 2015 to explore the use of LAMP-Vax in the prevention and treatment of allergic diseases, and is now focused on cancer immunotherapy. The LAMP platform has been tested in Phase I and II clinical studies. For more information, please visit www.immunomix.com.